116 related articles for article (PubMed ID: 21740293)
41. Understanding the role of MET kinase in cancer therapy.
Posadas EM; Figlin RA
J Clin Oncol; 2013 Jan; 31(2):169-70. PubMed ID: 23213104
[No Abstract] [Full Text] [Related]
42. Targeting the Met signaling pathway in renal cancer.
Giubellino A; Linehan WM; Bottaro DP
Expert Rev Anticancer Ther; 2009 Jun; 9(6):785-93. PubMed ID: 19496715
[TBL] [Abstract][Full Text] [Related]
43. MET inhibitors start on road to recovery.
Garber K
Nat Rev Drug Discov; 2014 Aug; 13(8):563-5. PubMed ID: 25082276
[No Abstract] [Full Text] [Related]
44. Emerging Opportunities for c-MET Visualization in the Clinic.
Pool M; van Dam GM; de Vries EG
J Nucl Med; 2016 May; 57(5):663-4. PubMed ID: 26823563
[No Abstract] [Full Text] [Related]
45. Combined treatment with MET inhibitors and other therapies in lung cancer.
Bagai R; Ma PC
Transl Lung Cancer Res; 2012 Sep; 1(3):214-8. PubMed ID: 25806183
[No Abstract] [Full Text] [Related]
46. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
[TBL] [Abstract][Full Text] [Related]
47. c-Met: A Promising Therapeutic Target in Bladder Cancer.
Feng Y; Yang Z; Xu X
Cancer Manag Res; 2022; 14():2379-2388. PubMed ID: 35967753
[TBL] [Abstract][Full Text] [Related]
48. The study of direct and indirect effects of radiofrequency ablation on tumor microenvironment in liver tumor animal model.
Jiang AN; Wang B; Wang S; Zhao K; Wu H; Yan K; Wu W; Yang W
BMC Cancer; 2022 Jun; 22(1):663. PubMed ID: 35710408
[TBL] [Abstract][Full Text] [Related]
49. Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.
Naidoo DB; Chuturgoon AA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575943
[TBL] [Abstract][Full Text] [Related]
50. Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.
Damalanka VC; Wildman SA; Janetka JW
Medchemcomm; 2019 Sep; 10(9):1646-1655. PubMed ID: 31803403
[TBL] [Abstract][Full Text] [Related]
51. Incidence and risk of fatigue in cancer patients treated with MET inhibitors: A systematic review and meta-analysis.
Tong H; Zhu Y; Liu Y
Medicine (Baltimore); 2019 May; 98(22):e15522. PubMed ID: 31145273
[TBL] [Abstract][Full Text] [Related]
52. Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung Adenocarcinoma.
Yang H; Jiang P; Liu D; Wang HQ; Deng Q; Niu X; Lu L; Dai H; Wang H; Yang W
Mol Ther Oncolytics; 2019 Sep; 14():82-93. PubMed ID: 31024988
[TBL] [Abstract][Full Text] [Related]
53. Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups.
Jiang Y; Zhang K; Gao S; Wang G; Huang J; Wang J; Chen L
Molecules; 2016 May; 21(5):. PubMed ID: 27187326
[TBL] [Abstract][Full Text] [Related]
54. Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.
Jin S; Borkhuu O; Bao W; Yang YT
J Clin Med Res; 2016 Apr; 8(4):284-96. PubMed ID: 26985248
[TBL] [Abstract][Full Text] [Related]
55. Hepatic Radiofrequency Ablation-induced Stimulation of Distant Tumor Growth Is Suppressed by c-Met Inhibition.
Ahmed M; Kumar G; Moussa M; Wang Y; Rozenblum N; Galun E; Goldberg SN
Radiology; 2016 Apr; 279(1):103-17. PubMed ID: 26418615
[TBL] [Abstract][Full Text] [Related]
56. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
57. Molecular determinants of lung cancer metastasis to the central nervous system.
Whitsett TG; Inge LJ; Dhruv HD; Cheung PY; Weiss GJ; Bremner RM; Winkles JA; Tran NL
Transl Lung Cancer Res; 2013 Aug; 2(4):273-83. PubMed ID: 25806243
[TBL] [Abstract][Full Text] [Related]
58. LncRNA expression profiles of EGFR exon 19 deletions in lung adenocarcinoma ascertained by using microarray analysis.
Wang Y; Chen W; Chen J; Pan Q; Pan J
Med Oncol; 2014 Sep; 31(9):137. PubMed ID: 25085781
[TBL] [Abstract][Full Text] [Related]
59. Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.
Szokol B; Gyulavári P; Kurkó I; Baska F; Szántai-Kis C; Greff Z; Orfi Z; Peták I; Pénzes K; Torka R; Ullrich A; Orfi L; Vántus T; Kéri G
ACS Med Chem Lett; 2014 Apr; 5(4):298-303. PubMed ID: 24900830
[TBL] [Abstract][Full Text] [Related]
60. Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway.
Liang Z; Ai J; Ding X; Peng X; Zhang D; Zhang R; Wang Y; Liu F; Zheng M; Jiang H; Liu H; Geng M; Luo C
ACS Med Chem Lett; 2013 Apr; 4(4):408-13. PubMed ID: 24900685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
